Daniel M. Jorgensen, M.D., MpH has had an accomplished career at both large pharmaceutical and earlier stage biotechnology companies. He has held senior leadership positions in the Global Research and Development Division at Pfizer, Inc. Most notably, Dr. Jorgensen led the Zmax (single-dose azithromycin) clinical development program, the dalbavancin (second generation glycolipopeptide) medical development team, and Pfizer's first vaccine development group. Prior to joining PolyMedix, he served as Vice President, Clinical Research at AMAG Pharmaceuticals, where he oversaw clinical trials across multiple medical areas. During his 25-year career in health care, Dr. Jorgensen has also worked at Aventis Pasteur, at the Centers for Disease Control and Prevention (CDC) as an Epidemic Intelligence Service Officer, and as Montana's State Medical Officer. Dr. Jorgensen received his BS degree from Yale, his MD from the University of Wisconsin, his MPH from the University of Washington, and his MBA from Yale. He is board-certified in three medical areas: pediatrics, infectious diseases, and preventive medicine.